Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gordon Campbell Weir, M.D.

Title
Institution
Department
Address
Phone
Fax

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. U42RR016606 (WEIR, GORDON CAMPBELL) Sep 30, 2001 - Aug 31, 2007
    NIH/NCRR
    HUMAN PANCREATIC ISLET CELL RESOURCE
    Role: Principal Investigator
  2. U19DK061251 (HABENER, JOEL F) Sep 30, 2001 - Sep 29, 2004
    NIH/NIDDK
    Program Project,Restoration of Endocrine Pancreas Funct*
    Role: Co-Principal Investigator
  3. P01DK053087 (WEIR, GORDON CAMPBELL) Feb 15, 1998 - Nov 30, 2003
    NIH/NIDDK
    ISLET XENOTRANSPLANTATION--GENETIC APPROACHES TO PROBLEM
    Role: Principal Investigator
  4. P30DK036836 (KING, GEORGE L) Feb 15, 1997 - Nov 30, 2001
    NIH/NIDDK
    Diabetes Research Center
    Role: Co-Principal Investigator
  5. R01DK050657 (WEIR, GORDON CAMPBELL) Feb 10, 1996 - May 31, 2000
    NIH/NIDDK
    Islet Transplantation - Protection by Immunobarriers
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Weir GC. A novel cellular engineering approach to diabetes mellitus. Nat Rev Endocrinol. 2020 Sep; 16(9):477-478. PMID: 32665618.
    Citations:    
  2. Weir GC, Gaglia J, Bonner-Weir S. ß-cell secretory dysfunction: a key cause of type 2 diabetes - Authors' reply. Lancet Diabetes Endocrinol. 2020 05; 8(5):370-371. PMID: 32333872.
    Citations:    
  3. Bose S, Volpatti LR, Thiono D, Yesilyurt V, McGladrigan C, Tang Y, Facklam A, Wang A, Jhunjhunwala S, Veiseh O, Hollister-Lock J, Bhattacharya C, Weir GC, Greiner DL, Langer R, Anderson DG. A retrievable implant for the long-term encapsulation and survival of therapeutic xenogeneic cells. Nat Biomed Eng. 2020 Aug; 4(8):814-826. PMID: 32231313.
    Citations:    
  4. Ebrahimi AG, Hollister-Lock J, Sullivan BA, Tsuchida R, Bonner-Weir S, Weir GC. Beta cell identity changes with mild hyperglycemia: Implications for function, growth, and vulnerability. Mol Metab. 2020 05; 35:100959. PMID: 32244186.
    Citations:    
  5. Weir GC, Gaglia J, Bonner-Weir S. Inadequate ß-cell mass is essential for the pathogenesis of type 2 diabetes. Lancet Diabetes Endocrinol. 2020 03; 8(3):249-256. PMID: 32006519.
    Citations:    
  6. Weir GC. Glucolipotoxicity, ß-Cells, and Diabetes: The Emperor Has No Clothes. Diabetes. 2020 03; 69(3):273-278. PMID: 31519699.
    Citations:    
  7. Farah S, Doloff JC, Müller P, Sadraei A, Han HJ, Olafson K, Vyas K, Tam HH, Hollister-Lock J, Kowalski PS, Griffin M, Meng A, McAvoy M, Graham AC, McGarrigle J, Oberholzer J, Weir GC, Greiner DL, Langer R, Anderson DG. Long-term implant fibrosis prevention in rodents and non-human primates using crystallized drug formulations. Nat Mater. 2019 08; 18(8):892-904. PMID: 31235902.
    Citations:    
  8. Aguayo-Mazzucato C, Andle J, Lee TB, Midha A, Talemal L, Chipashvili V, Hollister-Lock J, van Deursen J, Weir G, Bonner-Weir S. Acceleration of ß Cell Aging Determines Diabetes and Senolysis Improves Disease Outcomes. Cell Metab. 2019 07 02; 30(1):129-142.e4. PMID: 31155496.
    Citations:    
  9. Mahmoud AI, Galdos FX, Dinan KA, Jedrychowski MP, Davis JC, Vujic A, Rachmin I, Shigley C, Pancoast JR, Lee S, Hollister-Lock J, MacGillivray CM, Gygi SP, Melton DA, Weir GC, Lee RT. Apolipoprotein E is a pancreatic extracellular factor that maintains mature ß-cell gene expression. PLoS One. 2018; 13(10):e0204595. PMID: 30303984.
    Citations:    Fields:    
  10. Bochenek MA, Veiseh O, Vegas AJ, McGarrigle JJ, Qi M, Marchese E, Omami M, Doloff JC, Mendoza-Elias J, Nourmohammadzadeh M, Khan A, Yeh CC, Xing Y, Isa D, Ghani S, Li J, Landry C, Bader AR, Olejnik K, Chen M, Hollister-Lock J, Wang Y, Greiner DL, Weir GC, Strand BL, Rokstad AMA, Lacik I, Langer R, Anderson DG, Oberholzer J. Alginate encapsulation as long-term immune protection of allogeneic pancreatic islet cells transplanted into the omental bursa of macaques. Nat Biomed Eng. 2018 Nov; 2(11):810-821. PMID: 30873298.
    Citations:    
  11. Hwa AJ, Weir GC. Transplantation of Macroencapsulated Insulin-Producing Cells. Curr Diab Rep. 2018 06 16; 18(8):50. PMID: 29909496.
    Citations: 1     Fields:    
  12. Weir GC, Ehlers MR, Harris KM, Kanaparthi S, Long A, Phippard D, Weiner LJ, Jepson B, McNamara JG, Koulmanda M, Strom TB. Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics. Pediatr Diabetes. 2018 08; 19(5):945-954. PMID: 29473705.
    Citations: 1     Fields:    
  13. Evron Y, Colton CK, Ludwig B, Weir GC, Zimermann B, Maimon S, Neufeld T, Shalev N, Goldman T, Leon A, Yavriyants K, Shabtay N, Roze